Clinical Trial Update: Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating zanidatamab plus standard-of-care versus standard-of-care alone in advanced HER2-positive biliary tract cancer; the study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Zanidatamab

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Biliary Tract Cancer | Phase 3 | Status: RECRUITING